A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

October 3, 2023

Study Completion Date

December 31, 2025

Conditions

Breast CancerHER2+ Breast Cancer

Interventions

BIOLOGICAL

VRP-HER2

VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2

BIOLOGICAL

Pembrolizumab

A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.

Trial Locations (1)

Duke University, Durham

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Herbert Lyerly

OTHER

NCT03632941 - A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | Biotech Hunter | Biotech Hunter